Journal Pre-proof Use of a Risk Stratification Tool to Guide Evaluation of Patients with Asymptomatic Microscopic Hematuria Results in Significant Cost Savings Without Compromising Detection of Significant Cancers or Lesions Daniel E. Rabinowitz M.D. , Andrew M. Wood M.D. , Allison Marziliano PhD , Andre Perez-Orozco B.S. , Andrew Ng M.D. , Michael A. Diefenbach PhD , Patrick Samson M.D. , Manish A. Vira M.D. , Justin Han M.D. , Ariel Schulman M.D. , Simon J. Hall M.D. PII: S0090-4295(20)30373-3 DOI: https://doi.org/10.1016/j.urology.2020.03.045 Reference: URL 22072 To appear in: Urology Received date: 2 December 2019 Revised date: 9 March 2020 Accepted date: 29 March 2020 Please cite this article as: Daniel E. Rabinowitz M.D. , Andrew M. Wood M.D. , Allison Marziliano PhD , Andre Perez-Orozco B.S. , Andrew Ng M.D. , Michael A. Diefenbach PhD , Patrick Samson M.D. , Manish A. Vira M.D. , Justin Han M.D. , Ariel Schulman M.D. , Simon J. Hall M.D. , Use of a Risk Stratification Tool to Guide Evaluation of Patients with Asymp- tomatic Microscopic Hematuria Results in Significant Cost Savings Without Compromising Detection of Significant Cancers or Lesions, Urology (2020), doi: https://doi.org/10.1016/j.urology.2020.03.045 This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2020 Published by Elsevier Inc.